Skip to main content
SpringerLink
Log in

The role of calcium antagonists in patients with chronic renal failure

  • Editorial Commentary
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

The objective of antihypertensive treatment in patients with chronic renal failure, many of whom have elevated blood pressure levels, is to reduce cardiovascular events and to slow down the progression of kidney function impairment. Calcium antagonists have been shown to be effective and safe antihypertensive drugs in patients from different age groups, including children. On the basis of numerous studies, one may conclude that the main benefit of antihypertensive therapy is because of the blood pressure lowering effect per se and that calcium antagonists do not differ from other antihypertensive drugs in the ability to prevent cardiovascular complications of hypertension. In particular, calcium antagonists are not inferior to other groups of antihypertensive agents in the prevention of coronary artery disease. There is, however, now evidence from controlled clinical trials that drugs interfering with the renin–angiotensin system are more beneficial than other antihypertensive agents in patients with chronic renal failure. Thus, several studies have demonstrated that ACE-inhibitors and, in patients with type-2 diabetic nephropathy, AT 1-antagonists are superior to other classes of antihypertensive drugs, including calcium antagonists, in delaying the progression of renal insufficiency. Therefore, in hypertensive patients with chronic renal failure antihypertensive treatment should be initiated with a drug that inhibits the renin–angiotensin system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. US Renal data system (1999) USRDS 1999 Annual Data Report, Bethesda, MD, USA

  2. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Int Med 134:629–636

    CAS  PubMed  Google Scholar 

  3. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold L, Wedel H, Zanchetti A (2001) Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 12:218–225

    CAS  PubMed  Google Scholar 

  4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo jr JL, Jones DW, Materson BJ, Oparil S, Wright jr JT, Roccella EJ (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289:2560–2572

    Article  CAS  PubMed  Google Scholar 

  5. Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011–1053

    PubMed  Google Scholar 

  6. Cristofori P, Lanzoni A, Quartaroli M, Pastorino AM, Zancanaro C, Cominacini L, Gaviraghi G, Turton J (2000) The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens 18:1429–1438

    Article  CAS  PubMed  Google Scholar 

  7. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P (2002) Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106:2422–2427

    Article  CAS  PubMed  Google Scholar 

  8. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CA (1990) Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335:827–838

    Article  CAS  PubMed  Google Scholar 

  9. Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362:1527–1535

    Article  CAS  PubMed  Google Scholar 

  10. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C (2002) Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 61:2157–2164

    Article  CAS  PubMed  Google Scholar 

  11. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snappin SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869

    Article  CAS  PubMed  Google Scholar 

  12. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860

    Article  CAS  PubMed  Google Scholar 

  13. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers, G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003

    Article  CAS  PubMed  Google Scholar 

  14. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 21:875–886

    Article  CAS  PubMed  Google Scholar 

  15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031

    Article  CAS  PubMed  Google Scholar 

  16. Weber MA, Julius J, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363:2049–2051

    Article  CAS  PubMed  Google Scholar 

  17. Yusuf S, Sleight P, Dagenais G, Montague T, Bosch J, Pogue J, Taylor W, Sardo L (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153

    Article  PubMed  Google Scholar 

  18. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, De Jong PE, De Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS (2001) Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131–1140

    Article  CAS  PubMed  Google Scholar 

  19. Agadoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek DA, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CL, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller III ER, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright jr JT, Yu S (2001) Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 285:2719–2728

    Article  PubMed  Google Scholar 

  20. Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106:672–678

    Article  CAS  PubMed  Google Scholar 

  21. Ruggenenti P, Fassi A, Parvanova Ilieva A, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951

    Article  CAS  PubMed  Google Scholar 

  22. Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285:685–688

    CAS  PubMed  Google Scholar 

  23. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting- enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–1462

    Article  CAS  PubMed  Google Scholar 

  24. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961

    Article  CAS  PubMed  Google Scholar 

  25. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945

    Article  CAS  PubMed  Google Scholar 

  26. Ruggenenti P, Perna A, Mosconi L, Matalone M, Garini G, Salvadori M, Zoccali C, Scolari F, Maggiore Q, Tognoni G, Remuzzi G (1997) Randomised placebo-controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy. Lancet 349:1857–1863

    Article  PubMed  Google Scholar 

  27. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364

    Article  CAS  PubMed  Google Scholar 

  28. Hilgers KF, Dötsch J, Rascher W, Mann JFE (2004) Treatment strategies in patients with chronic renal disease: ACE-inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 19:956–961

    Article  PubMed  Google Scholar 

  29. Wright jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek DA, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288:2421–2431

    Article  CAS  PubMed  Google Scholar 

  30. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, Saul JP (2004) A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 145:353–359

    Article  CAS  PubMed  Google Scholar 

  31. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, Tou, C, Kilbaner M (2003) Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 18:548–553

    PubMed  Google Scholar 

  32. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660–665

    Article  PubMed  Google Scholar 

  33. Scharer K, Alatas H, Bein G (1977) The treatment of renal hypertension with verapamil in childhood. Monatsschr Kinderheilk 125:706–712

    CAS  Google Scholar 

  34. Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S (2002) Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 17:35–40

    Article  PubMed  Google Scholar 

  35. Flynn JT, Warnick SJ (2002) Isradipine treatment of hypertension in children: a single center experience. Pediatr Nephrol 17:748–753

    Article  PubMed  Google Scholar 

  36. Von Vigier RO, Franscini LMD, Bianda NDF, Pfister R, Aebischer CC, Bianchetti MG (2001) Antihypertensive efficacy of amlodipine in children with chronic renal diseases. J Hum Hypertens 15:387–391

    Article  PubMed  Google Scholar 

  37. Wühl E, Mehls O, Schaefer F, and the ESCAPE Trial Group (2004) Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 66:768–776

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Münster Medical School, c/o Potstiege 42, 48161, Münster, Germany

    Karl Heinz Rahn

Authors
  1. Karl Heinz Rahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Heinz Rahn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rahn, K.H. The role of calcium antagonists in patients with chronic renal failure. Pediatr Nephrol 20, 1208–1213 (2005). https://doi.org/10.1007/s00467-005-1982-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-005-1982-x

Keywords

Search

Navigation